Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kimball

Showing results (291-300 of 373) with videos related to

Pageof 38
Sort By:
Experimental Dermatology|February 4, 2022
Yin and Yang of skin microbiota in "swimmer acne"Peyton C Morss-Walton, Jean S McGee, Monica Rosales Santillan, et al.
The British Journal of Dermatology|July 6, 2022
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2018
Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trialK A Papp, A Blauvelt, A B Kimball, et al.
Archives of Dermatology|October 11, 2002
Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10Alexa B Kimball, Tatsuyoshi Kawamura, Krupali Tejura, et al.
The Journal of Dermatological Treatment|May 7, 2015
Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacyTeresa L Kauf, Jui-Chen Yang, Alexa B Kimball, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|November 29, 2013
A general route for 13C-labeled fluorenols and phenanthrenols via palladium-catalyzed cross-coupling and one-carbon homologationRuilian Wu, L A Pete Silks, Morgane Olivault-Shiflett, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeksAnne Lynn S Chang, Maria Alora-Palli, Xinaida T Lima, et al.
Journal of the American Academy of Dermatology|February 5, 2025
Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled studyLindsay S Ackerman, Bethanee J Schlosser, Tianyu Zhan, et al.
JAMA Dermatology|February 3, 2021
Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Alexa B Kimball, Lyn Guenther, Sunil Kalia, et al.
Journal of the American Academy of Dermatology|May 14, 2010
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialRichard G Langley, Steven R Feldman, Chenglong Han, et al.
Pageof 38

Showing results (291-300 of 373) with videos related to

Sort By:
Pageof 38
Experimental Dermatology|February 4, 2022
Yin and Yang of skin microbiota in "swimmer acne"Peyton C Morss-Walton, Jean S McGee, Monica Rosales Santillan, et al.
The British Journal of Dermatology|July 6, 2022
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2018
Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trialK A Papp, A Blauvelt, A B Kimball, et al.
Archives of Dermatology|October 11, 2002
Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10Alexa B Kimball, Tatsuyoshi Kawamura, Krupali Tejura, et al.
The Journal of Dermatological Treatment|May 7, 2015
Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacyTeresa L Kauf, Jui-Chen Yang, Alexa B Kimball, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|November 29, 2013
A general route for 13C-labeled fluorenols and phenanthrenols via palladium-catalyzed cross-coupling and one-carbon homologationRuilian Wu, L A Pete Silks, Morgane Olivault-Shiflett, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeksAnne Lynn S Chang, Maria Alora-Palli, Xinaida T Lima, et al.
Journal of the American Academy of Dermatology|February 5, 2025
Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled studyLindsay S Ackerman, Bethanee J Schlosser, Tianyu Zhan, et al.
JAMA Dermatology|February 3, 2021
Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Alexa B Kimball, Lyn Guenther, Sunil Kalia, et al.
Journal of the American Academy of Dermatology|May 14, 2010
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialRichard G Langley, Steven R Feldman, Chenglong Han, et al.
Pageof 38